Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180255 · ClinicalTrials.gov registry record · Phase 2
Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery
A Phase 2 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT03180255 is a Phase 2 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 101 participants.
The verdict
NCT03180255, a Phase 2 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens (IOL).
Interventions
- OTHER Placebo
- COMBINATION_PRODUCT Dexamethasone phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180255
The ClinicalTrials.gov registry entry for NCT03180255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyegate Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03180255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03180255 about?
NCT03180255 is a clinical study titled "Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery". Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens (IOL).
What is the current status of trial NCT03180255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2017-07-26. Estimated completion is 2017-11-27.
What interventions are being tested in trial NCT03180255?
The interventions under investigation include: Placebo (OTHER), Dexamethasone phosphate (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03180255?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.